Ian Ratcliffe

EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight products on the market, including Caphosol for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, ProstaScint for imaging the extent and spread of prostate cancer, Quadramet for the treatment of pain in patients whose cancer has spread to the bones, Erwinase and Kidrolase for the treatment of acute lymphoblastic leukemia and the antibiotic surgical implant Collatamp. EUSA also has several products in late-stage development, notably Collatamp topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx bupivacaine implant for local post-surgical pain control. Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $1 billion company by the beginning of the next decade.

Adimab LLC provides human therapeutic antibodies. The firm has discovered antibodies for a wide variety of therapeutic targets within many disease areas, including oncology, immunomodulation, inflammation, neuroscience and pain, cardiovascular and metabolic disease and infectious disease. The company was founded in 2007 by Tillman Gerngross, Dane Wittrup and Errik Anderson and is headquartered in Lebanon, NH.

Auris Health, Inc. develops robotics technology for medical applications. The company was founded by Frederic H. Moll, Hariharan Sundram and Christopher J. P. Velis and is headquartered in Redwood City, CA.

SilverRail Technologies, Inc. provides technology solutions for the distribution of train tickets and other rail-related products. It offers SilverCore, a global rail distribution platform that brings railways and travel retailers together. The firm also offers SilverAPI that provides end-to-end booking services that comprise search, book, cancel, payment, and ticketing, SilverAgent Lite, a Web-based application that delivers travel management companies’ access to live reservations made through its online booking tool partners, and SilverAgent Pro, a Web-based application for travel professionals that provide staff with a Web interface to search, book, pay, ticket, and modify company global rail content. The company was founded by Aaron M. Gowell and William D. Phillipson in 2009 and is headquartered in Boston, MA.

Pollen, Inc. provides financial services. It provides C2FO market, working capital exchange that allows companies to optimize their working capital positions in a live, bid/ask environment. The firm serves buyers and suppliers who use the market to increase profit and accelerate cash flow between themselves. The company was founded by Alexander C. Kemper and Pete Thomas in May 2010 and is headquartered in Leawood, KS.

AppDirect, Inc. develops end-to-end commerce platform for selling, distributing, and managing cloud-based products and services. It offers AppMarket, AppReseller, AppBilling, and AppDistribution. The company was founded by Nicolas Desmarais, Andy Sen, and Daniel H. Saks in 2009 and is headquartered in San Francisco, CA.

Calliditas Therapeutics Suisse SA engages in the development of NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes, which amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company was founded Chihiro Yabe, Robert A. Clark, David Lambeth, and Karl-Heinz Krause in 2006 and is headquartered in Geneva, Switzerland.

Flex Logix Technologies, Inc. provides software services. Its products include embedded FPGA, SOC applications and EFLX compiler. The company was founded by Cheng Wang, Fang-Li Yuan and Geoffrey Tate in March 2014 and is headquartered in Mountain View, CA.

Helion Energy, Inc. manufactures power generation technology. It develops power plants that would produce electricity by running a nuclear-fusion reaction whereby atoms merge at extremely high temperatures. The company was founded by David Kirtley, John Slough, Chris Pihl and George Votroubek in 2009 and is headquartered in Redmond, WA.

Blacksky Holdings, Inc. provides integrated space products and services. The firm offers satellite design, rideshare launch management, global communications networking, and a geospatial intelligence service to support a new era of global awareness. The company was founded by Jason Andrews and Marian S. Joh in 1999 and is headquartered in Seattle, WA.

Axovan AG conducts biopharmaceutical research and develops pharmaceuticals. Active in pharmaceutical research and development, it focuses on the family of drug targets called G protein-coupled receptors (GPCRs), which are involved in a number of pathologies. It has developed a validated GPCR-based chemical library through its proprietary chem-informatics platform AXADDIS. Its lead product, clasozentan, is an intravenous endothelin receptor antagonist optimized for treating cerebral diseases. It is partnering non-core indication projects (pain, metabolic diseases, inflammation) at earlier stages. The company was founded in 2000 and is headquartered in Allschwil, Switzerland.

Borealis Ventures (Borealis Ventures) is a venture capital firm founded in 2001 by Jesse Devitte and Phil J. Ferneau. The firm is headquartered in Hanover, New Hampshire.

GlycoFi, Inc. develops biopharmaceutical products. It provides protein production technology to develop, produce and commercialize biotherapeutics products. The company was founded by Tillman Gerngross in 2000 and is headquartered in Lebanon, NH.

Genevest Consulting Group SA is an independent Swiss venture capital firm which was founded in 1983 to provide advisory services to institutional investors and high-net worth individuals. Based in Geneva, Genevest operates in close cooperation with Endeavour Vision SA.

Oak Ridge National Laboratory provides technical and scientific research services. The firm performs basic and applied research in principal areas such as neutron science, energy, supercomputing, advanced materials and national security. It also has research programs in nuclear and atomic physics, nuclear fusion, and microscopy. The company was founded in 1943 and is headquartered in Oak Ridge, TN.

DoubleDutch, Inc. develops mobile engagement applications for events, conferences, and trade shows. It offers platform, integrations, security, and live engagement marketing. The company was founded by Lawrence Stockton Coburn, Mathew Spolin, and Pankaj Prasad in January 2011 and is headquartered in San Francisco, CA.

Omega Fund Management Ltd. (OFM) is the wholly-owned private equity firm founded by Dr. Otello Stampacchia in 2004. The firm is headquartered in the US.

The National Academies of Sciences provides advisory services in the areas of science, technology, and health policy.

Mithril Capital Management LLC (Mithril Capital) is a venture capital firm founded in 2012 by Peter Andreas Thiel and Ajay Royan. The firm is headquartered in Austin, Texas.

SoniVie Ltd. engages in the development of a system for the treatment of pulmonary hypertension. Its products include Therapeutic Intra-Vascular Ultrasound (TIVUS) system, an intravascular, catheter-based technology that can cause denervation of nerves surrounding blood vessels and other structures like the bronchus. The company was founded by Moshe Arkin in 2014 and is headquartered in Rosh Haayin, Israel.

Oklo, Inc. constructs reactor and distributes power. The company was founded by Jacob DeWitte and Caroline Cochran and is headquartered in Mountain View, CA.

Anaconda Biomed SL manufactures healthcare devices. It develops catheters for mechanical thrombectomies. The company was founded by Marc Ribo and Ofir Arad and is headquartered in Barcelona, Spain.

Part of Sienna Biopharmaceuticals, Inc., Creabilis UK Ltd. engages in research and development of biological products. The company is based in Canterbury, UK.

BlackSky Global LLC develops satellite-imaging-as-a-service software. The company is headquartered in Seattle, WA.

Nuvation Bio Operating Co., Inc. engages in the provision of biotechnology company developing proprietary therapies focuse on oncology. It portfolio includes Seven Novel and Mechanistically Distinct Oncology Programs, Each with Multiple Drug Development Candidates. The company was founded by David Hung in 2018 and is headquartered in New York, NY.

Chord Therapeutics SA is a clinical stage pharmaceutical company. It develops drugs for patients with rare, life-threatening and severely disabling diseases. The firm offers CRD1. The company was founded by Arthur Roach and is headquartered in Geneva, Switzerland.

Amagma, Inc. provides healthcare services. The company is headquartered in Waltham, MA.

Ankyra Therapeutics, Inc. engages in the provision of healthcare services. The company is headquartered in Boston, MA.

CDR-Life Inc. is a Swiss biotherapeutics company that develops novel immunotherapies to target the power of the immune system specifically to tumor cells. CDR-Life is based in Schlieren, Switzerland, and was founded in 2017 by Leonardo Borras, Christian Leisner, Dominik Escher, Rouven Bingel-Erlenmeyer, and Konstantin von Schulthess. The company's proprietary antibody platform targets intracellular tumor antigens presented on the major histocompatibility complex (MHC) with high affinity and specificity, which allows them to develop a pipeline of first-in-class therapeutics across a broad range of solid tumors. The company is backed by leading cross-Atlantic investors and has an existing collaboration and licensing agreement with Boehringer Ingelheim for a novel antibody fragment therapy to treat macular degeneration. Christian Leisner has been the CEO since 2017.

Part of Grey Orange Pte Ltd., Grey Orange International, Inc. is a company that provides technology related services. The company is based in Roswell, GA. The CEO of the company is Samay Kohli.

NRG Therapeutics Ltd. is a British neuroscience drug discovery company that focuses on building a pipeline of disease-modifying mitochondrial therapeutics to slow or halt the progression of neurodegenerative disorders such as Parkinson's and ALS. The company is based in Stevenage, UK, and was founded in 2018 by Neil Miller and Richard Rutter. The company's pre-clinical pipeline of small molecule assets is based on inhibiting the mitochondrial permeability transition pore (mptp) through a novel mechanism of action. Inhibition of the mptp has been shown to protect neurons, reduce neuroinflammation, and extend survival in pre-clinical disease models. Neil Miller has been the CEO since 2018.

The Thiel Foundation awards grants to groups that empower people to improve their lives, champions organizations and individuals who expose human rights abuses and authoritarianism. It programs include The Thiel Fellowship, Breakout Labs and Imitatio. The company is headquartered in San Francisco, CA.